Implant Sciences Continues to Innovate - Granted 3 More US Patents for Trace Detection
Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that the company has been granted three new patents by the U.S. Patent and Trademark Office.
The patents, captioned "Non-Radioactive Ion Source Using High Energy Electrons", "Chemical Analysis Using Hyphenated Low and High Field Ion Mobility", and "Selective Ionization Using High-Frequency Filtering of Reactive Ions," expand Implant Sciences' intellectual property protection and are expected to lead to even more effective company products.
Military Radar Systems Market Outlook 2016-2026
"Implant Sciences is committed to providing the best and most innovative technology for our customers. We believe that the first of these three new patents, our newest non-rad ionization method, gives Implant Sciences a true competitive advantage in the field. This new design is durable, low-cost, and is compatible with high-volume manufacturing. We believe that the design, which also makes the unit easier to service in the field, will further simplify trace detection ownership and increase customer satisfaction," noted Todd Silvestri, Implant Sciences' Vice President of Technology.
"Implant Sciences' other two new patents seek to dramatically improve some of the inherent limitations associated with the conventional ionization physics and chemistry currently deployed in ion mobility systems, primarily False Alarm Rates (FAR) and selectivity. The innovation in these two patents, namely hyphenating of Ion Mobility Spectrometry (IMS) and Differential Mobility Spectrometry (DMS), leads to an even higher system resolution, which increases the range of detectable threats for the system," stated Dr. Bill McGann, CEO of Implant Sciences.
"Being able to select the type of reactive ions we want to generate, via the high-frequency filtering patent, adds another dimension of separation, leading to improved selectivity. Both of these patents should allow us to detect and identify a broader range of threats, including homemade explosives (HMEs), masking agents, and other new threats. We expect this will lead to important, real-life implications for our customers, where lives depend on technology such as ours to detect emerging terrorist threats," Dr. McGann added.
Source : Implant Sciences Corporation
Nov 9 - 10, 2016 - Washington, United States